10 Biggest Price Target Changes For Monday
Keybanc lifted Netflix, Inc. (NASDAQ: NFLX) price target from $645 to $670. Netflix shares rose 0.1% to $633.00 in pre-market trading.
HC Wainwright & Co. Maintains Buy on Capricor Therapeutics, Raises Price Target to $14
HC Wainwright & Co. analyst Joseph Pantginis maintains Capricor Therapeutics (NASDAQ:CAPR) with a Buy and raises the price target from $9 to $14.
12 Health Care Stocks Moving In Wednesday’s After-Market Session
Gainers
TransCode Therapeutics (NASDAQ:RNAZ) shares increased by 5.4% to $2.73 during Wednesday's after-market session. The company's market cap stands at $35.2 million.
Capricor Stock Is Moving Higher As Duchenne Dystrophy Cell Therapy Slows Disease Progression By 71%
Capricor Therapeutics Inc (NASDAQ:CAPR) has announced final data from Phase 2 HOPE-2 trial of CAP-1002 for advanced stages of Duchenne muscular…
Capricor Therapeutics Reports Final Data From Phase 2 HOPE-2 Trial In Patients With Duchenne Muscular Dystrophy Treated With CAP-1002: Trial Met Primary Efficacy Endpoint
–Trial Met its Primary Efficacy Endpoint of Mid-level Performance of Upper Limb (PUL) v1.2 (p=0.01)–
–Additional Positive Endpoints of Full PUL v2.0 (p=0.04) and Cardiac Endpoint of Ejection
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical readouts and IPOs were among the catalysts for the week.
Capricor Therapeutics To Present Final Data From HOPE-2 Trial With CAP-1002 In Duchenne Muscular Dystrophy At World Muscle Society 2021
Capricor Therapeutics (NASDAQ:CAPR) ("Capricor" or "the Company"), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and